News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC (AZN)



10/3/2007 8:52:08 AM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc. today announced that rights to pediatric asthma development programs that include CyDex’s Captisol-Enabled® technology have been acquired from Verus Pharmaceuticals, Inc. by AstraZeneca.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES